Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized Trial Investigating Bortezomib (NSC 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

Trial Profile

A Phase III Randomized Trial Investigating Bortezomib (NSC 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)

Suspended
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2018

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Daunorubicin; Dexamethasone; Dexamethasone; Doxorubicin; Etoposide; Folinic acid; Folinic acid; Hydrocortisone; Ifosfamide; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Pegaspargase; Tioguanine; Vincristine
  • Indications Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2018 Planned primary completion date changed from 15 Feb 2022 to 31 Dec 2023.
    • 31 Aug 2018 Biomarkers information updated
    • 20 Nov 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top